Krebs Biochemicals & Industries Ltd - Stock Valuation and Financial Performance

BSE: 524518 | NSE: KREBSBIO | Pharmaceuticals & Drugs | Small Cap

Krebs Biochem.&Inds Share Price

61.55 -2.27 -3.56%
as on 28-Mar'24 16:01

DeciZen - make an informed investing decision on Krebs Biochem.&Inds

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality

2. Valuation

Undervalued

3. Price Trend

Krebs Biochemicals & Industries stock performance -

mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
131.6 Cr.
52-wk low:
51.1
52-wk high:
93.2

Is Krebs Biochemicals & Industries Ltd an attractive stock to invest in?

1. Is Krebs Biochemicals & Industries Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Krebs Biochemicals & Industries Ltd is a below average quality company.

2. Is Krebs Biochemicals & Industries Ltd undervalued or overvalued?

The key valuation ratios of Krebs Biochemicals & Industries Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

3. Is Krebs Biochemicals & Industries Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Krebs Biochemicals & Industries Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Krebs Biochem.&Inds:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Krebs Biochemicals & Industries Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Sep'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % -4.3%-8.1%-27.5%-29.8%-32.1%-40.5%-61.5%-43.7%-59.8%-29.8%-
Value Creation
Index
-1.3NA-3.0-3.1NANANANANANA-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 001.33.533.847.833.453.759.752.150
Sales YoY Gr.-NANA173.6%856.9%41.4%-30.1%60.7%11.2%-12.7%-
Adj EPS -3.5-20.1-12.9-11.4-12.4-12.1-16-14.5-20.7-11.5-9.7
YoY Gr.-NANANANANANANANANA-
BVPS (₹) 2.9-9.36.91-12.5-8.6-18.1-23.9-34.8-46.1-52.6
Adj Net
Profit
-3.5-19.8-17.4-16.2-17.6-20.1-28.9-28.4-44.5-24.7-21
Cash Flow from Ops. 39.4-90.5-15.3-11.2-6.23.9-35.5-14.6-17.2-24.7-
Debt/CF from Ops. 1.9-1.4-2-4.2-9.113.7-1.9-7.6-8.3-7.4-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NA9.1%16%-12.7%
Adj EPS NANANANA
BVPS-235.9%NANANA
Share Price 12.9% -11.9% -12.7% 14.7%

Key Financial Parameters

Performance Ratio Colour Code Guide

Sep'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
-75.1-90.6-111.2-224.2216.4125.314783.775.628.319.6
Op. Profit
Mgn %
00-961.7-226.6-22.2-20.4-55.5-32.7-56.9-30.3-20.5
Net Profit
Mgn %
00-1349.5-460.1-52.2-42.1-86.4-52.8-74.6-47.4-41.7
Debt to
Equity
25.9-13.33.332.2-3.2-3.7-2-2.4-1.9-1.8-
Working Cap
Days
007,1061,48820115824317921823156
Cash Conv.
Cycle
001,149366-17-32-11210-124

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 15.99%

Return on Equity has declined versus last 3 years average to 19.60%

Sales growth is not so good in last 4 quarters at -6.71%

Latest Financials - Krebs Biochemicals & Industries Ltd.

Standalone Consolidated
TTM EPS (₹) -9.7 -
TTM Sales (₹ Cr.) 49.9 -
BVPS (₹.) -52.6 -
Reserves (₹ Cr.) -135 -
P/BV -1.16 -
PE 0.00 -
From the Market
52 Week Low / High (₹) 51.10 / 93.20
All Time Low / High (₹) 9.10 / 293.59
Market Cap (₹ Cr.) 132
Equity (₹ Cr.) 21.6
Face Value (₹) 10
Industry PE 48.2

Management X-Ray of Krebs Biochem.&Inds:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Krebs Biochem.&Inds

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSSep'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales0014344833546052
Operating Expenses 451412415852719468
Manufacturing Costs2142131617263323
Material Costs0001132316264126
Employee Cost 1266111415151516
Other Costs 2233444453
Operating Profit -4-5-12-8-8-10-19-18-34-16
Operating Profit Margin (%) ---961.0%-226.0%-22.2%-20.4%-55.5%-32.7%-56.9%-30.3%
Other Income 0010000111
Interest 0413566653
Depreciation 0244445567
Exceptional Items 0300-100000
Profit Before Tax -4-8-16-16-18-20-29-28-45-25
Tax 0000000000
Profit After Tax -4-8-16-16-18-20-29-28-45-25
PAT Margin (%) ---1,265.5%-454.0%-52.8%-41.9%-86.4%-52.8%-74.6%-47.4%
Adjusted EPS (₹)-4.4-8.0-12.1-11.3-12.5-12.0-16.0-14.5-20.7-11.5
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSSep'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 4-591-18-14-33-47-75-99
Share Capital 10101314141718202222
Reserves -6-14-4-12-32-31-51-67-97-121
Minority Interest0000000000
Debt26582543525066111143183
Long Term Debt22582543525066101133173
Short Term Debt3000000101010
Trade Payables20171211182123213815
Others Liabilities 87386967748578758476
Total Liabilities 136107116122126142134159190175

Fixed Assets

Gross Block164167213227230234243261288303
Accumulated Depreciation114116120124129133138143149156
Net Fixed Assets515193102101101105118139147
CWIP 771144341284
Investments 0000000000
Inventories3156512915172612
Trade Receivables1002030011
Cash Equivalents 06000170100
Others Assets473779989121611
Total Assets 136107116122126142134159190175

Cash Flow

(All Figures are in Crores.)
PARTICULARSSep'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 49-45-15-11-64-35-15-17-25
PBT -4-11-17-16-17-20-29-28-45-25
Adjustment 093116109121110
Changes in Working Capital 55-39-1-2914-16216-10
Tax Paid 0000000000
Cash Flow From Investing Activity 0-3-4-5-3-4-10-23-23-13
Capex 0-34-13-4-5-9-18-27-15
Net Investments 0000000000
Others 00-8921-2-543
Cash Flow From Financing Activity -4954131691729384037
Net Proceeds from Shares 0191940251910130
Net Proceeds from Borrowing -34358179-2153300
Interest Paid 00000-6-6-6-5-3
Dividend Paid 0000000000
Others -150-14-501003240
Net Cash Flow 06-60017-171-10
PARTICULARSSep'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)-75.26N/A-683.34-296.7N/AN/AN/AN/AN/AN/A
ROCE (%)-3.91N/A-25.38-27.13N/AN/AN/AN/AN/AN/A
Asset Turnover Ratio000.010.030.270.360.240.370.340.29
PAT to CFO Conversion(x)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Working Capital Days
Receivable Days005284101217245
Inventory Days001,4365739379131107129131
Payable Days0003,559414310507305264378

Krebs Biochemicals & Industries Ltd Stock News

Krebs Biochemicals & Industries Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Krebs Biochem.&Inds on 28-Mar-2024 16:01 is ₹61.55.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Mar-2024 16:01 the market cap of Krebs Biochem.&Inds stood at ₹131.6.
The latest P/E ratio of Krebs Biochem.&Inds as of 28-Mar-2024 16:01 is 0.00.
The latest P/B ratio of Krebs Biochem.&Inds as of 28-Mar-2024 16:01 is -1.16.
The 52-week high of Krebs Biochem.&Inds is ₹93.20 and the 52-week low is ₹51.10.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Krebs Biochem.&Inds is ₹49.91 ( Cr.) .

About Krebs Biochemicals & Industries Ltd

Krebs Biochemicals & Industries (KBIL) was established in the year 1991 as a Public Limited Company with the main objective of establishing commercially viable biotech processes with applications in Medicine, Agriculture Industry. The company has pioneered in the fermentation technology over the last decade.

KBIL went into public in the year March 1994 to part finance its fermentation technology project. KBIL has a strong shareholding community of over 10000 spread across all parts of the country.

KBIL’s manufacturing Unit-I is located at Regadichelika Village, Nellore Dist., Andhra Pradesh, India. Products manufactured from Unit I facility are Ephedrine, Pseudoephedrine and their salts, which are used for making formulations for respiratory ailments, viz., cough, cold etc.

The facility at Unit II is being used to manufacture a basket of fermentation products viz., Lovastatin, Simvastatin, (all cholesterol reducing agents) and Vitamin C and its salts (neutraceuticals), which has wider applications in pharma, feeds, foods beverages etc. The company is focussing on the research and development of new bio molecules and genetically engineered products by synthetic and biological approaches. The manufacturing facility is developed in an area of 83.79 acres and comprises of Administration Block, Fermentation Block, Extraction Column, Hydrogenation & Synthetic Blocks, Quality Control Department, Quality Assurance Block, Ware House, Pseudoephedrine Block, Solvent Yard and Canteen etc.

KBIL has received ISO 9002 certification for its Unit-I situated at Nellore from Yarsley International Certifications Services accredited by United Kingdom Accreditation Services (U.K.A.S.) in the year 2001. Unit I is also accredited with European Certificate of Suitability from European Directorate for the Quality of Medicines (EDQM).

Product range of the company includes:

Bulk activities

Synthetic

  • Lavastatin
  • Simvastatin
  • I -Ephedrochiloride
  • l - Ephedrine Sulphate
  • l - Ephedrine Base (Liquid)
  • d - Pseudoephedrine Hydrochloride
  • d - Pseudoephedrine Sulphate
  • d - Pseudoephedrine Base
  • dl - Ephedrine Base
  • n - Methyl Ephedrine
  • d - Ephedrine Bitartarate
  • Vitamin C
  • Vitamin C (Coated)

Herbal

  • Calcium Sennosides - 20% & 60%
  • Garcinia Combogia Powdered Extract
  • Capsaicin - 50/100

Intermediates

  • Crude Lovastatin
  • Simvastatin Ammonium Salt

Products in pipeline

  • Pravastatin Sodium

Achievements/ recognition:

  • ISO 9002 in November 2001 
  • EDQM July 2003 
  • USFDA in November 2003 
  • ISO 9001 – 2000 in March 2004 
  • WHO GMP certification in November 2002 and renewed in March 2005
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.